Darya-Varia Laboratoria Tbk
PT Darya-Varia Laboratoria Tbk manufactures and trades pharmaceutical products and cosmetics in Indonesia. It operates in four segments: Prescription Drugs, Consumer Health Products, Export and Toll Manufacturing Services, and Services. The company offers prescription products in various areas of cardiology, analgesics, gastro-hepatology, dermamedic, somatic, cough and cold, antibiotic, women hea… Read more
Darya-Varia Laboratoria Tbk (DVLA) - Net Assets
Latest net assets as of June 2025: Rp1.49 Trillion IDR
Based on the latest financial reports, Darya-Varia Laboratoria Tbk (DVLA) has net assets worth Rp1.49 Trillion IDR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rp2.40 Trillion) and total liabilities (Rp904.97 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rp1.49 Trillion |
| % of Total Assets | 62.26% |
| Annual Growth Rate | 9.33% |
| 5-Year Change | 9.25% |
| 10-Year Change | 48.84% |
| Growth Volatility | 8.91 |
Darya-Varia Laboratoria Tbk - Net Assets Trend (2000–2024)
This chart illustrates how Darya-Varia Laboratoria Tbk's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Darya-Varia Laboratoria Tbk (2000–2024)
The table below shows the annual net assets of Darya-Varia Laboratoria Tbk from 2000 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Rp1.45 Trillion | +3.17% |
| 2023-12-31 | Rp1.40 Trillion | +0.06% |
| 2022-12-31 | Rp1.40 Trillion | +1.65% |
| 2021-12-31 | Rp1.38 Trillion | +4.11% |
| 2020-12-31 | Rp1.33 Trillion | +1.55% |
| 2019-12-31 | Rp1.31 Trillion | +8.82% |
| 2018-12-31 | Rp1.20 Trillion | +7.52% |
| 2017-12-31 | Rp1.12 Trillion | +3.40% |
| 2016-12-31 | Rp1.08 Trillion | +10.89% |
| 2015-12-31 | Rp973.52 Billion | +1.15% |
| 2014-12-31 | Rp962.43 Billion | +5.22% |
| 2013-12-31 | Rp914.70 Billion | +8.69% |
| 2012-12-31 | Rp841.55 Billion | +15.61% |
| 2011-12-31 | Rp727.92 Billion | +13.63% |
| 2010-12-31 | Rp640.60 Billion | +15.44% |
| 2009-12-31 | Rp554.92 Billion | +9.27% |
| 2008-12-31 | Rp507.85 Billion | +9.87% |
| 2007-12-31 | Rp462.23 Billion | +12.11% |
| 2006-12-31 | Rp412.31 Billion | +5.56% |
| 2005-12-31 | Rp390.60 Billion | +22.44% |
| 2004-12-31 | Rp319.03 Billion | +16.65% |
| 2003-12-31 | Rp273.48 Billion | +20.43% |
| 2002-12-31 | Rp227.09 Billion | +38.84% |
| 2001-12-31 | Rp163.55 Billion | -3.89% |
| 2000-12-31 | Rp170.17 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Darya-Varia Laboratoria Tbk's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 110927585700000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rp1.11 Trillion | 76.56% |
| Common Stock | Rp280.00 Billion | 19.32% |
| Other Comprehensive Income | Rp-18.58 Billion | -1.28% |
| Other Components | Rp78.27 Billion | 5.40% |
| Total Equity | Rp1.45 Trillion | 100.00% |
Darya-Varia Laboratoria Tbk Competitors by Market Cap
The table below lists competitors of Darya-Varia Laboratoria Tbk ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Eastern Power Group Public Company Limited
BK:EP
|
$8.74 Million |
|
Ikena Oncology Inc
NASDAQ:IKNA
|
$8.74 Million |
|
S&K Polytec Co. Ltd
KQ:091340
|
$8.74 Million |
|
Chicago Rivet & Machine Co
NYSE MKT:CVR
|
$8.74 Million |
|
Korea Information Engineering Services Co. Ltd
KQ:039740
|
$8.73 Million |
|
North Energy ASA
OL:NORTH
|
$8.73 Million |
|
PIL ITALICA LIFESTYLE LIMITED
NSE:PILITA
|
$8.73 Million |
|
Peloton Minerals Corporation
OTCQB:PMCCF
|
$8.73 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Darya-Varia Laboratoria Tbk's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,404,432,093,000 to 1,448,971,508,000, a change of 44,539,415,000 (3.2%).
- Net income of 156,147,303,000 contributed positively to equity growth.
- Dividend payments of 120,960,000,000 reduced retained earnings.
- Other comprehensive income increased equity by 9,352,112,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rp156.15 Billion | +10.78% |
| Dividends Paid | Rp120.96 Billion | -8.35% |
| Other Comprehensive Income | Rp9.35 Billion | +0.65% |
| Total Change | Rp- | 3.17% |
Book Value vs Market Value Analysis
This analysis compares Darya-Varia Laboratoria Tbk's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.24x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.25x to 1.24x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | Rp495.47 | Rp1610.00 | x |
| 2010-12-31 | Rp571.97 | Rp1610.00 | x |
| 2011-12-31 | Rp649.93 | Rp1610.00 | x |
| 2012-12-31 | Rp751.38 | Rp1610.00 | x |
| 2013-12-31 | Rp816.70 | Rp1610.00 | x |
| 2014-12-31 | Rp862.45 | Rp1610.00 | x |
| 2015-12-31 | Rp872.39 | Rp1610.00 | x |
| 2016-12-31 | Rp967.43 | Rp1610.00 | x |
| 2017-12-31 | Rp1000.34 | Rp1610.00 | x |
| 2018-12-31 | Rp1075.56 | Rp1610.00 | x |
| 2019-12-31 | Rp1167.44 | Rp1610.00 | x |
| 2020-12-31 | Rp1184.18 | Rp1610.00 | x |
| 2021-12-31 | Rp1242.33 | Rp1610.00 | x |
| 2022-12-31 | Rp1253.23 | Rp1610.00 | x |
| 2023-12-31 | Rp1253.96 | Rp1610.00 | x |
| 2024-12-31 | Rp1293.72 | Rp1610.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Darya-Varia Laboratoria Tbk utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.78%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.48%
- • Asset Turnover: 0.97x
- • Equity Multiplier: 1.49x
- Recent ROE (10.78%) is below the historical average (14.40%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 27.98% | 11.57% | 1.70x | 1.42x | Rp40.82 Billion |
| 2003 | 16.96% | 11.89% | 1.04x | 1.37x | Rp19.05 Billion |
| 2004 | 15.61% | 11.67% | 0.99x | 1.35x | Rp17.91 Billion |
| 2005 | 18.32% | 13.24% | 0.98x | 1.41x | Rp32.52 Billion |
| 2006 | 12.74% | 9.11% | 1.03x | 1.35x | Rp11.28 Billion |
| 2007 | 10.80% | 9.80% | 0.91x | 1.21x | Rp3.69 Billion |
| 2008 | 13.94% | 12.26% | 0.91x | 1.26x | Rp20.03 Billion |
| 2009 | 13.02% | 8.32% | 1.11x | 1.41x | Rp16.78 Billion |
| 2010 | 17.31% | 11.93% | 1.09x | 1.33x | Rp46.82 Billion |
| 2011 | 16.61% | 12.44% | 1.05x | 1.28x | Rp48.12 Billion |
| 2012 | 17.69% | 13.69% | 1.01x | 1.28x | Rp64.75 Billion |
| 2013 | 13.75% | 11.42% | 0.93x | 1.30x | Rp34.33 Billion |
| 2014 | 8.41% | 7.33% | 0.89x | 1.28x | Rp-15.31 Billion |
| 2015 | 11.08% | 8.26% | 0.95x | 1.41x | Rp10.54 Billion |
| 2016 | 14.09% | 10.48% | 0.95x | 1.42x | Rp44.13 Billion |
| 2017 | 14.53% | 10.30% | 0.96x | 1.47x | Rp50.62 Billion |
| 2018 | 16.72% | 11.81% | 1.01x | 1.40x | Rp80.63 Billion |
| 2019 | 16.98% | 12.23% | 0.99x | 1.40x | Rp91.18 Billion |
| 2020 | 12.22% | 8.86% | 0.92x | 1.50x | Rp29.44 Billion |
| 2021 | 10.53% | 7.71% | 0.91x | 1.50x | Rp7.36 Billion |
| 2022 | 10.64% | 7.79% | 0.95x | 1.43x | Rp9.01 Billion |
| 2023 | 10.42% | 7.74% | 0.93x | 1.45x | Rp5.89 Billion |
| 2024 | 10.78% | 7.48% | 0.97x | 1.49x | Rp11.25 Billion |
Industry Comparison
This section compares Darya-Varia Laboratoria Tbk's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,199,532,212,232
- Average return on equity (ROE) among peers: 20.74%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Darya-Varia Laboratoria Tbk (DVLA) | Rp1.49 Trillion | 27.98% | 0.61x | $8.73 Million |
| Indofarma Tbk (INAF) | $292.57 Billion | 37.70% | 0.84x | $4.64 Million |
| Merck Tbk (MERK) | $416.74 Billion | 25.87% | 0.37x | $11.17 Million |
| Phapros Tbk PT (PEHA) | $821.61 Billion | 12.42% | 1.55x | $4.50 Million |
| Pyridam Farma Tbk (PYFA) | $118.93 Billion | 7.10% | 0.57x | $77.92 Million |
| Sido Muncul PT (SIDO) | $2.90 Trillion | 22.87% | 0.15x | $190.71 Million |
| Tempo Scan Pacific Tbk (TSPC) | $2.64 Trillion | 18.49% | 0.36x | $67.10 Million |